For most people who use it, Ozempic produces significant weight loss, averaging about 12% of body weight over 68 weeks in clinical trials. Whether that result is “worth it” depends on how you weigh the cost (up to $499 per month without insurance), the side effects (nausea affects roughly 1 in 5 users), and the fact that stopping the medication typically means regaining the weight. Here’s what the evidence actually shows so you can make that calculation for yourself.
How Much Weight You Can Expect to Lose
A meta-analysis of randomized controlled trials found that people taking semaglutide (the active ingredient in Ozempic) lost an average of 12.1% of their body weight compared to placebo over at least 68 weeks. For someone starting at 220 pounds, that translates to roughly 27 pounds. Results don’t take that long to start showing up: participants in major studies lost about 3.8% of their body weight in just the first four weeks, and around 9.6% by three months.
Those are averages, though, and individual results vary widely. Some people lose considerably more, others less. The dose gets gradually increased over the first several months, so the most noticeable appetite suppression and weight loss tend to accelerate after the initial low-dose period.
How It Actually Works in Your Body
Semaglutide mimics a gut hormone called GLP-1 that your body naturally releases after eating. It works on multiple fronts at once. In your digestive system, it slows down how quickly food leaves your stomach, which keeps you feeling full longer. It also improves how your body handles blood sugar by boosting insulin and dialing back glucagon.
The more interesting effects happen in the brain. Semaglutide activates receptors in areas of the hypothalamus and brainstem that control hunger and fullness. Certain neurons in the hypothalamus, when activated by the drug, send inhibitory signals that essentially tell your brain to stop eating. Think of it as the brain hitting the brakes on hunger before you’ve physically overfilled your stomach. The drug also acts on reward pathways, which is why many users report that food simply becomes less interesting to them, not just that they feel full sooner.
The Side Effects Are Real
Gastrointestinal problems are the most common downside. Across studies of GLP-1 drugs like semaglutide, nausea affected about 21% of users. Diarrhea hit roughly 11%, vomiting about 9%, and constipation around 8%. Most people find these side effects are worst during the first few weeks and during dose increases, then taper off. But for some, they persist and become a reason to quit.
A more subtle concern is muscle loss. In the landmark STEP-1 trial, participants who lost an average of 15.3 kg saw about 6.9 kg of that come from lean mass, not fat. That means roughly 45% of the weight lost was lean tissue, which is considerably higher than the general rule of thumb that about one-quarter of weight loss comes from muscle. This is particularly relevant for older adults, where preserving muscle matters for mobility and long-term health. Resistance training while on the medication can help counteract this, and most clinicians now recommend it.
What Happens When You Stop
This is the part that gives many people pause. A systematic review published in The BMJ found that people who stopped taking newer, more effective weight management medications like semaglutide regained an average of 9.9 kg (about 22 pounds) within the first year. The projected timeline for returning to baseline weight was approximately 1.5 years after stopping treatment.
That pattern holds across virtually all weight loss medications, not just semaglutide. The implication is straightforward: for most people, Ozempic is not a short-term fix. It works as long as you take it, and the weight comes back when you don’t. That reframes the cost question significantly, because you’re not budgeting for a few months of treatment. You’re potentially looking at years or indefinitely.
What It Costs
The manufacturer currently offers Ozempic at $499 per month for self-pay patients at the highest dose (2 mg), with lower doses available at $349 per month. New patients can access introductory pricing of $199 per month for the first two fills at lower doses. If you have commercial insurance and use the manufacturer’s savings card, your cost could drop to as little as $25 per month for up to 48 months.
The gap between those numbers is enormous, and it’s the single biggest factor in whether Ozempic is “worth it” in practical terms. At $25 a month with good insurance, the cost-benefit math is easy for most people. At $499 a month out of pocket, indefinitely, the calculus changes dramatically. Check your specific insurance formulary before assuming coverage, as policies vary widely and some plans cover the diabetes indication but not weight management.
Benefits Beyond the Scale
Weight loss alone doesn’t capture the full picture. The SELECT trial, a large cardiovascular outcomes study, found that semaglutide reduced major adverse cardiovascular events by 20% in people with obesity and established heart disease who did not have diabetes. That includes heart attacks, strokes, and cardiovascular death. For someone with existing heart disease, that risk reduction is a meaningful benefit that goes well beyond cosmetic weight loss.
Many users also report improvements in blood pressure, cholesterol, blood sugar levels, joint pain, sleep quality, and energy. These secondary benefits can be substantial, particularly for people whose excess weight is actively worsening other health conditions.
How It Compares to Tirzepatide
Tirzepatide, sold as Zepbound for weight loss, works on two hormone pathways instead of one. In clinical trials, people without diabetes who took the highest dose of tirzepatide lost an average of 18% of their body weight, with some losing up to 21%. That’s noticeably more than semaglutide’s 12% average. The dual-action approach appears to produce stronger results for most people, though it comes with a similar side effect profile and similar weight regain concerns after stopping.
If maximizing weight loss is the primary goal and both options are available to you, tirzepatide has the edge in trial data. But availability, insurance coverage, and individual response all matter. Some people respond better to one medication than the other.
An Important Note on Ozempic Specifically
Ozempic is FDA-approved for type 2 diabetes and cardiovascular risk reduction in diabetic patients. It is not officially approved for weight loss in people without diabetes. The same active ingredient, semaglutide, is approved for weight management under the brand name Wegovy, typically at a higher dose. Many doctors prescribe Ozempic off-label for weight loss, which is legal and common, but it can affect insurance coverage and the dose you’re prescribed. If weight loss is your primary goal, ask about Wegovy as well, since it may be easier to get covered for that specific indication.
For people who have significant weight to lose, who can access the medication at a manageable price, and who understand it as a long-term commitment rather than a temporary solution, semaglutide delivers consistent, clinically meaningful results backed by strong evidence. The tradeoffs are real: ongoing cost, gastrointestinal side effects, muscle loss that needs to be actively managed, and weight regain if you stop. But for many people, particularly those with weight-related health risks, the benefits outweigh those downsides considerably.